Clear cell renal cell carcinoma (ccRCC), accounting for 80–90% of renal malignancies, is frequently driven by VHL inactivation—either through mutation or promoter hypermethylation—resulting in constitutive HIF2α activation and pseudohypoxic signaling. The gene discussed is EPAS1; the disease is clear cell renal carcinoma.